Clinical Guides
Neuropathic Pain: Assessment and Safer Medicine Trials
A source-grounded guide to recognising neuropathic pain, treating its cause and functional impact, and using monitored, time-limited medicine trials rather than unsupervised escalation or long-term opioid substitution.
MedNext Academy | 12 min read
Neuropathic Pain: Assessment and Safer Medicine Trials
A source-grounded guide to recognising neuropathic pain, treating its cause and functional impact, and using monitored, time-limited medicine trials rather than unsupervised escalation or long-term opioid substitution.
Summary
Neuropathic pain results from a lesion or disease of the somatosensory nervous system. Burning, electric-shock, shooting pain, pins and needles, numbness, allodynia and pain in a neuroanatomical distribution support the diagnosis, but no adjective proves it. First identify the cause and urgent threats: diabetes, post-herpetic pain, radiculopathy, cancer, traumatic nerve injury, HIV, chemotherapy, spinal disease, nutritional deficiency, alcohol, stroke and entrapment have different investigations and disease-directed treatments. Persistent pain deserves a functional assessment of sleep, mobility, work, mood and participation, not an analgesic-only encounter.
Current guidelines recommends a choice of amitriptyline, duloxetine, gabapentin or pregabalin as initial pharmacological treatment for adult neuropathic pain other than trigeminal neuralgia. If an initial medicine is ineffective or not tolerated, offer one of the remaining medicines and consider further switching after unsuccessful trials. [current guidelines, recommendations 1.1.8–1.1.9.] This is a shared decision about a monitored trial, not evidence that all four medicines are interchangeable or safe in every person. Baseline renal function, frailty, falls, sedation, mental health, pregnancy potential, alcohol/substance use, interacting medicines and the specific diagnosis matter.
Start one intervention at a time whenever possible, agree a measurable outcome and arrange early review of titration, benefit, adverse effects and adherence. current guidelines explains that treatment is usually begun at a low dose and increased gradually to maximum individual benefit; adverse effects may stop further increase. [current guidelines, patient information: Getting the dose right.] Current guidelines requires early review after starting or changing treatment and regular review of pain control, sleep and participation, wellbeing, adverse effects and continued need. [current guidelines, recommendations 1.1.5–1.1.6.] A partial pain-score change without better function may not justify harm. When changing or withdrawing treatment, taper according to dose and discontinuation symptoms; do not abruptly stop an antidepressant or dependence-forming medicine. [current guidelines, recommendation 1.1.7.]
Tramadol is limited to acute rescue therapy in the current guidelines non-specialist pathway. current guidelines says not to start long-term tramadol, morphine, cannabis extract, capsaicin patch or several anticonvulsants without specialist advice. [current guidelines, recommendations 1.1.10–1.1.12.] That opioid boundary protects against tolerance, dependence, sedation, falls and interaction harm while preserving urgent symptom relief under supervision. Trigeminal neuralgia is an exception: Current guidelines offers carbamazepine initially and advises specialist input if it fails, is not tolerated or is contraindicated. [current guidelines, recommendations 1.1.13–1.1.14.]
The guide intentionally does not supply dose, titration, renal adjustment or pregnancy schedules. These are medicine-specific prescribing claims requiring the live local formulary and specialist/pharmacy advice. Pregabalin's label requires adult dose adjustment in reduced renal function and gradual withdrawal over at least one week; the exact regimen depends on indication and kidney function. [DailyMed pregabalin label, sections 2.1 and 2.7.] Pregnancy planning must be documented before gabapentinoid or other relevant exposure. UK regulatory advice reports that pregabalin exposure in pregnancy may slightly increase the chance of physical birth abnormalities, while the absolute risk remains low; never stop it abruptly without prescriber review. [pharmaceutical regulators, Pregabalin and risks in pregnancy.]
How Common Is It?
Neuropathic pain is a mechanism-based syndrome across diabetes, shingles, nerve trauma, spinal disease, cancer and neurological disease, so a single prevalence figure is rarely useful at the bedside. The meaningful burden is functional: sleep disruption, reduced mobility, depression, lost work, medication adverse effects and repeated unplanned consultation. A service should measure timely diagnosis of the cause, access to pain/condition-specific referral, safe medicine review and use of opioid rescue rather than claim a local frequency without a valid population source.
Some people have mixed nociceptive and neuropathic pain; forcing a binary label can miss arthritis, myofascial pain, spasticity, depression or unsafe analgesic exposure. The pain drawing, symptom time course and sensory examination should guide investigation. If pain is severe or significantly limits lifestyle, daily activity, sleep or participation, current guidelines supports referral to pain or condition-specific specialist services at any stage. [current guidelines, recommendation 1.1.2.]
In India, diabetes, cancer, trauma and spine disease are common pathways into neuropathic symptoms, but access to neurologists, pain services, MRI, physiotherapy, mental-health care and regulated medicines varies. The response should be staged, realistic and documented—not automatic polypharmacy.
Risk Factors
Risk rises with diabetes, herpes zoster, chemotherapy, HIV, alcohol exposure, B-vitamin deficiency, renal disease, trauma, surgery, amputation, radiculopathy, spinal cord disease, stroke and cancer. Ask about the underlying illness, duration, distribution, weakness, gait change, bowel/bladder symptoms, rash, fever, weight loss, trauma and prior treatment. New rapidly progressive neurological deficit, a sensory level, acute retention, systemic cancer symptoms or spinal-infection features requires urgent assessment rather than a chronic-pain prescription.
Medicine risk is practical. Sedating medicines increase falls and driving risk; kidney dysfunction can change exposure to renally cleared agents; antidepressant and opioid combinations can create interaction and withdrawal problems. For pregabalin, renal clearance is central to the labelled adjustment requirement. [DailyMed pregabalin label, section 2.7.] Gabapentinoids carry respiratory-depression risk, especially with respiratory or neurological disease, renal impairment, older age or concurrent CNS depressants. [pharmaceutical regulators, Pregabalin: reports of severe respiratory depression.] Pregnancy, breastfeeding, contraception and conception plans need review before treatment. current guidelines specifically directs clinicians to anti-epileptic-drug pregnancy safety advice and recommends tapering withdrawal according to dose and discontinuation symptoms. [current guidelines, recommendations 1.1.7 and 1.1.12.]
Screen for depression, anxiety, sleep disturbance, alcohol/substance use, cognitive impairment and social barriers. These do not make pain unreal; they determine whether a medicine trial is safe and whether psychological, sleep or rehabilitation care should run alongside it. Ask specifically about opioids, benzodiazepines, Z-drugs and alcohol before adding a gabapentinoid, and record the discussion of sedation, driving and emergency breathing symptoms.
Diagnosis
Diagnosis combines a plausible neurological lesion/disease, characteristic pain and compatible distribution. Do not diagnose neuropathic pain solely because pain is chronic or severe.
History
Map the pain, sensory loss, evoked pain, weakness, autonomic symptoms, triggers, nocturnal symptoms, rash, trauma, surgery, cancer and diabetes. Review sleep, mood, work, falls, driving, alcohol and all prescribed/non-prescribed medicines. Ask about pregnancy possibility and prior withdrawal symptoms.
Examination
Compare sensation, pinprick, temperature, light touch, vibration, reflexes, power, gait and skin change across a neuroanatomical distribution. Look for allodynia, hyperalgesia, weakness, ulceration, infection and vascular compromise. Document baseline function before treatment.
Investigations
Select tests for the suspected cause: glucose/HbA1c, renal/liver function, B12, infection tests, imaging, neurophysiology or cancer work-up as indicated. Investigations are not a substitute for urgent red-flag assessment. Review renal function and current medicines before any drug that may accumulate or interact; use local prescribing systems for exact adjustments.
Differential Diagnosis
Consider nociceptive musculoskeletal pain, inflammatory arthritis, visceral disease, vascular pain, complex regional pain syndrome, migraine, restless legs, primary headache, depression-related distress and medication-induced symptoms. A person may have more than one mechanism. Pain after a rash may be post-herpetic neuralgia, but new painful blistering may be active zoster; radicular symptoms may reflect a treatable compressive lesion; burning feet can accompany diabetes, alcohol, B12 deficiency or small-fibre disease.
Trigeminal neuralgia is not managed by the general initial-drug list: Current guidelines recommends carbamazepine initially. [current guidelines, recommendation 1.1.13.] Facial pain that is atypical, persistent, associated with sensory loss, weakness, rash or dental symptoms needs reassessment.
Worsening pain after starting treatment may be an adverse effect, inadequate diagnosis, poor adherence, withdrawal, substance use or disease progression. Before adding another analgesic, establish what changed and whether there is a neurological, infectious or oncological emergency.
Management
Treat cause, function and pain together. Optimise diabetes care, antiviral/infectious disease care, cancer treatment, decompression or rehabilitation where relevant; use physiotherapy, pacing, sleep support, psychological care and occupational adaptation when functional limits persist. Set a realistic aim such as safer walking, sleep improvement or return to work, not a promise of zero pain.
For non-trigeminal neuropathic pain, offer one of amitriptyline, duloxetine, gabapentin or pregabalin after individual risk review. [current guidelines, recommendation 1.1.8.] Make only one planned change at a time and review early. If ineffective or poorly tolerated, switch to one of the remaining choices rather than stacking medicines without a clear benefit–harm rationale. [current guidelines, recommendations 1.1.4–1.1.9.] Capsaicin cream may be considered for localised pain when oral treatment is avoided or not tolerated. [current guidelines, recommendation 1.1.11.]
Use tramadol only as acute rescue therapy in this pathway. Long-term tramadol, morphine and other listed medicines require specialist advice. [current guidelines, recommendations 1.1.10–1.1.12.] Refer early for severe pain, marked functional restriction, deteriorating underlying disease, diagnostic uncertainty, repeated failures, significant adverse effects, pregnancy complexity or opioid concern.
Record the medicine, target, current dose from the chart, titration plan from the local formulary, adverse effects, driving advice, next review and withdrawal plan. This makes a medication trial reversible and auditable.
Prescribing Information
Do not use this guide as a dose chart. Current guidelines supports four initial choices for non-trigeminal neuropathic pain but does not remove medicine-specific obligations for renal adjustment, hepatic disease, falls, mental health, pregnancy, breastfeeding, interactions and withdrawal. [current guidelines, recommendations 1.1.5–1.1.9.] Obtain current pharmacy/formulary advice before prescribing.
Choose according to the diagnosis and the person, not by a fixed ladder. Duloxetine may be unsuitable with particular interacting serotonergic or hepatotoxic medicines; a tricyclic may be poorly tolerated where anticholinergic burden, orthostatic symptoms or cardiac risk is material; gabapentinoids require renal and sedation assessment. These are prompts for a live interaction check, not an exhaustive contraindication list. Start low and titrate gradually only at planned reviews; do not make several sedating changes together. [current guidelines, patient information: Getting the dose right.]
At every early review, assess benefit, sleep, participation, adverse effects and continued need, exactly as Current guidelines requires. [current guidelines, recommendation 1.1.6.] When switching, plan overlap carefully to avoid loss of pain control; when withdrawing, taper for the individual dose and discontinuation symptoms. [current guidelines, recommendations 1.1.4 and 1.1.7.] The pregabalin label specifies gradual withdrawal over at least one week, but its dose and renal table must be taken from current product information rather than copied into this guide. [DailyMed pregabalin label, sections 2.1 and 2.7.]
Tramadol is acute rescue only; long-term tramadol and morphine should not be started in non-specialist care without specialist advice. [current guidelines, recommendations 1.1.10–1.1.12.] Avoid assuming that a higher dose or a second sedating drug is safer than referral. Pregabalin with opioids or other CNS depressants can contribute to respiratory depression; take urgent action for shallow breathing or profound sedation. [pharmaceutical regulators, Pregabalin: reports of severe respiratory depression.] Pregnancy safety, contraception and fetal risk are agent-specific; confirm current Indian product information and specialist advice before any change.
Document renal function, all CNS-active drugs, alcohol/substance risk, falls/driving advice and who will review the treatment. If the trial is unsuccessful, stop safely rather than leaving an ineffective medicine indefinitely. Do not frame any listed medicine as nationally available in India: procurement, registration and local protocols vary.
When to Refer
Refer urgently for acute weakness, sensory level, new retention/incontinence, cauda-equina symptoms, spinal infection or malignancy features, severe rapidly progressive pain with neurological loss, suicide risk, overdose or dangerous withdrawal. These are not routine pain-clinic referrals.
Consider pain or condition-specific referral at any stage for severe pain, significant restriction of life, sleep or participation, or deterioration in the underlying condition, matching current guidelines recommendation 1.1.2. Refer also for trigeminal neuralgia not responding to/tolerating carbamazepine, complex cancer pain, pregnancy medication decisions, renal complexity, repeated medicine failure or need for a non-specialist-forbidden treatment.
In India, specify the referral destination and bridge plan: diabetic foot/neurology, oncology, spine surgery, rehabilitation, mental health, physiotherapy or pain service. Give a medication list, current renal function, prior trials and response; a referral that omits prior adverse effects invites unsafe repetition.
Red Flags
Emergency reassessment is needed for new severe weakness, saddle symptoms, bowel/bladder change, rapidly evolving sensory loss, fever with back pain, cancer red flags, painful cold limb, spreading rash with eye involvement, acute confusion, overdose, falls or suicidal thoughts.
Medication red flags include excessive sedation, respiratory compromise, serious rash, severe mood change, withdrawal symptoms, escalating rescue-opioid use, alcohol/sedative co-use and pregnancy exposure. Stop-or-switch decisions require clinical review; abrupt cessation can be harmful. current guidelines instructs tapering during withdrawal or switching. [current guidelines, recommendation 1.1.7.]
Pain that becomes severe despite a correctly conducted trial is a reason to revisit diagnosis and refer, not to add unmonitored opioids. current guidelines permits specialist referral at any stage when pain severely limits function or underlying disease deteriorates. [current guidelines, recommendation 1.1.2.]
Indian Clinical Context
India-specific care must distinguish availability from appropriateness. A medicine being inexpensive, sold locally or previously prescribed does not prove it is indicated, safe in renal impairment or suitable in pregnancy. Use the hospital formulary and registered product information; do not claim national availability from this guide.
Prioritise treatable causes and functional care where specialist pain access is limited: diabetes control, foot protection, post-zoster review, cancer pathways, rehabilitation, sleep and mental-health support. Where a specialist is distant, teleconsultation and a clear early-review date are safer than serial dose escalation.
Explain opioid boundaries respectfully. A person in severe pain needs assessment and relief, but long-term tramadol/morphine initiation in the current guidelines non-specialist pathway is not routine. [current guidelines, recommendation 1.1.12.] Document access barriers and a transfer plan rather than leaving a patient on an ineffective sedating combination.
NMC Competency Mapping
This guide integrates Medicine, Neurology, Pharmacology, Psychiatry, Rehabilitation and AETCOM. Learners should identify a neuropathic distribution, examine sensory and motor function, recognise urgent spinal/neurological red flags, identify a reversible cause and explain why medicine trials need planned review. Exact NMC codes must be verified locally. [NMC, Competency Based Medical Education Curriculum, undergraduate portal.]
In a prescribing exercise, require a drug-interaction, renal, pregnancy, fall and withdrawal check before selecting an initial medicine. The learner should quote the four current guidelines initial choices, distinguish trigeminal neuralgia, and state that dose and titration come from the current formulary.
Assessment should reward functional goals, respectful pain communication, safe opioid boundaries and timely referral—not recall of a dose without patient context.
Key Exam Pearls for NEET PG
Neuropathic pain is linked to a lesion or disease of the somatosensory system and commonly presents with burning, electric or shooting pain, altered sensation and allodynia. Establish cause and exclude neurological emergencies.
For adults with non-trigeminal neuropathic pain, current guidelines offers amitriptyline, duloxetine, gabapentin or pregabalin initially; if ineffective/not tolerated, switch among the remaining options. [current guidelines, recommendations 1.1.8–1.1.9.]
Tramadol is acute rescue only, capsaicin cream may be considered for localised pain when oral options are avoided, and long-term tramadol/morphine are not for non-specialist initiation without advice. [current guidelines, recommendations 1.1.10–1.1.12.]
Review early, measure function, taper withdrawal and remember that trigeminal neuralgia uses carbamazepine initially. [current guidelines, recommendations 1.1.5–1.1.7 and 1.1.13.]
Frequently Asked Questions
Which medicines are initial options for non-trigeminal neuropathic pain?
Current guidelines offers amitriptyline, duloxetine, gabapentin or pregabalin. Choice must account for diagnosis, renal function, interaction risk, pregnancy potential, falls, mental health and patient preference. Begin one medicine at a low dose and increase gradually only through planned review; use current local formulary and product information for the actual regimen. [current guidelines, recommendation 1.1.8 and patient information: Getting the dose right.]
Can tramadol become routine long-term neuropathic-pain treatment?
Not in the current guidelines non-specialist pathway. Tramadol may be considered only for acute rescue, while long-term tramadol and morphine should not be started without specialist advice. Escalating rescue-opioid use, alcohol or sedative co-use, or sedation without functional benefit should trigger reassessment and usually specialist input rather than automatic renewal. [current guidelines, recommendations 1.1.10–1.1.12.]
Should a neuropathic pain medicine be stopped suddenly if it is ineffective?
No. current guidelines says withdrawal or switching should be tapered to account for dose and discontinuation symptoms. Arrange a review and a documented plan instead of abrupt cessation. Pregabalin's label specifically requires gradual discontinuation over at least one week, with the individual schedule based on current dose, indication and clinical context. [current guidelines, recommendation 1.1.7; DailyMed pregabalin label, section 2.1.]
When is specialist referral appropriate for neuropathic pain?
At any stage when pain is severe, significantly limits daily activity, sleep or participation, or the underlying condition is deteriorating. Referral is also appropriate for diagnostic uncertainty, red flags, complex medicine safety, pregnancy medication decisions, opioid concern or repeated treatment failure. Send the pain or condition-specific service the diagnosis, distribution, renal function, medication history, benefit, adverse effects and agreed functional target. [current guidelines, recommendation 1.1.2.]
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic